LENZ Therapeutics is on track for FDA review of LNZ100 for presbyopia treatment with a PDUFA target action date of August 8, 2025. They have hired an 88-member sales force for immediate marketing upon approval. International licensing agreements for LNZ100 have brought over $195 million in payments and royalties. As of June 30, 2025, LENZ has $209.6 million in cash, cash equivalents, and marketable securities.

The FDA is reviewing LNZ100 for presbyopia treatment, with a PDUFA target action date of August 8, 2025. No Advisory Committee Meeting is planned. LENZ is ready to launch in the U.S. with an 88-member sales force. International agreements have brought over $195 million in payments. Financially, the company has $209.6 million in cash and securities.

LENZ Therapeutics signed licensing agreements for LNZ100 in different regions, including a $125 million deal with Lotus Pharmaceutical for South Korea and Southeast Asia. A $70 million agreement with Laboratoires Théa for Canada was also announced. In China, an NDA for LNZ100 was submitted under a Development and Commercialization Agreement with CORXEL. As of June 30, 2025, LENZ had $209.6 million in cash, cash equivalents, and marketable securities.

Financially, LENZ reported $209.6 million in cash, cash equivalents, and marketable securities as of June 30, 2025, enough to fund operations post-launch. Research and development expenses increased to $9.1 million in Q2 2025. Selling, general, and administrative expenses also rose to $12.8 million in Q2 2025. Net loss for Q2 2025 was $14.9 million.

LENZ Therapeutics is focused on developing and commercializing LNZ100, an aceclidine-based eye drop for presbyopia. The FDA has a target action date of August 8, 2025, for LNZ100. LENZ has signed international agreements and has a strong financial position with $209.6 million in cash, cash equivalents, and marketable securities as of June 30, 2025.

Read more at GlobeNewswire: LENZ Therapeutics Reports Second Quarter 2025 Financial